|Systematic (IUPAC) name|
|14px (what is this?)|
4-HO-MPMI (also known as 4-Hydroxy-N-methyl-(α,N-trimethylene)tryptamine or lucigenol) is a tryptamine derivative that is a psychedelic drug. It was developed by the team led by David Nichols from Purdue University in the late 1990s. This compound produces hallucinogen-appropriate responding in animal tests with a similar potency to the amphetamine-derived psychedelic DOI, and has two enantiomers, with only the (R)-enantiomer being active.
The binding affinity for 5-HT2A receptor is 13 +/- 2 nM (Ki [125I]DOI). It is reported at doses starting at 0.5 mg and 1.0-1.5 mg seem to be psychedelic doses. The duration it is reported between six to eight hours. The effects, still not too documented, are OEV/CEV, sedation and anxiety.[unreliable source?]
- Gerasimov M, Marona-Lewicka D, Kurrasch-Orbaugh DM, Qandil AM, Nichols DE (1999). "Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain". Journal of Medicinal Chemistry 42 (20): 4257–4263. PMID 10514296. doi:10.1021/jm990325u.